查看购物车
  • Traditional Chinese
  • Japanese
非渗出性视网膜疾病治疗药市场报告(2025年)
市场调查报告书
商品编码
1849631

非渗出性视网膜疾病治疗药市场报告(2025年)

2025 Nonexudative Retinal Disease Pharmaceuticals Market Report
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

新到信息

"非渗出性视网膜疾病治疗市场报告（2025）" 提供了干性老年黄斑部病变 (AMD) 和其他非渗出性视网膜疾病的最新疾病预测，并包含了补体抑制剂、基因治疗药物和其他新兴治疗类别的最新预测。

今年的报告追踪了药物递送技术的进展，这些技术正在扩大临床阶段药物开发计画的范围并提高治疗的持久性。报告中还包含了美国医生使用补体抑制剂经验的最新调查数据，以及关于美国和西欧医生如何看待和计划采用基因治疗技术的最新见解。

"2025年非渗出性视网膜疾病治疗市场报告" 全面分析了当前及新兴的干性老年黄斑变性 (AMD) 和其他非渗出性视网膜疾病的治疗方法，并按地区进行了划分。我们评估了补体抑制剂、基因疗法、缓释技术、抗氧化剂等，并检视了关键市场趋势、患者经济状况、报销趋势以及五年成长预测。

本报告也提供了详细的销售和价值需求预测、产品类别市场占有率，并对19家主要竞争对手进行了概况介绍，探讨了他们的策略和前景。

目录

"2025年非渗出性视网膜疾病治疗市场报告" 以清晰的数据为依据，展现了干性老年性黄斑部病变 (AMD) 和其他非渗出性视网膜疾病治疗领域不断发展的格局。

主要内容：

  • 疾病概述与危险因子：探讨非渗出性视网膜疾病，包括其病因、疾病进展及其与整体健康和生活方式的关係。
  • 诊断与治疗现况：探讨诊断技术、病患管理趋势、药物介入日益重要的角色。
  • 全球视网膜照护现况：概述全球视网膜照护服务、病患就医途径、专科医师分布、治疗方案采纳趋势。
  • 现有疗法：分析已核准的药物和生物製剂、市场渗透率、定价趋势、竞争格局等。
  • 在研药物：回顾正在研发中的研究性药物，这些药物有望引领下一代治疗，包括辅助抑制剂、基因疗法和缓释装置。
  • 公司简介及临床前活动：介绍正在开发或销售非渗出性视网膜疾病治疗药物的公司，以及其他进行临床前计画的公司。
简介目录

What's New:

The "2025 Nonexudative Retinal Disease Pharmaceuticals Market Report" features updated disease estimates for geographic atrophy and other nonexudative retinal conditions and fresh forecasts for complement inhibitors, gene therapies, and other emerging treatment classes.

This year's edition expands coverage of clinical-stage drug development programs and tracks progress in drug-delivery technologies designed to improve treatment durability. It also includes new survey data on US physician experience with complement inhibitors and updated insights into how doctors in the US and Western Europe view and plan to adopt gene therapy techniques.

The "2025 Nonexudative Retinal Disease Pharmaceuticals Market Report" delivers a comprehensive analysis of current and emerging therapies for geographic atrophy, dry AMD, and other nonexudative retinal diseases. It evaluates complement inhibitors, gene therapies, sustained-release technologies, antioxidants, and more-examining key market trends, patient economics, reimbursement dynamics, and five-year growth forecasts.

The report also includes detailed unit and dollar demand projections, product category market shares, and profiles of 19 leading competitors with insights into their strategies and outlooks.

Contents:

The "2025 Nonexudative Retinal Disease Pharmaceuticals Market Report" provides a clear, data-driven view of the evolving treatment landscape for geographic atrophy, dry AMD, and other nonexudative retinal diseases.

Coverage highlights include:

  • Disease overview and risk factors: discussion of nonexudative retinal diseases, their causes, disease progression, and links to systemic health and lifestyle.
  • Diagnosis and treatment landscape: examination of diagnostic technologies, patient management trends, and the growing role of pharmaceutical intervention.
  • Global retinal care environment: overview of global retinal care delivery, patient access, specialist distribution, and treatment adoption trends.
  • Current therapies in the market: analysis of approved pharmaceuticals and biologics, including market penetration, pricing dynamics, and competitive positioning.
  • Development pipeline: review of investigational agents in development-complement inhibitors, gene therapies, sustained-release devices, and more-shaping the next generation of care.
  • Company profiles and preclinical activity: profiles of companies developing or marketing therapies for nonexudative retinal disease, plus a listing of additional firms with preclinical programs.